Stock Overview

DexCom Inc (DXCM)

NASDAQ · Healthcare · Medical Devices

DexCom Inc is a Healthcare company with a market capitalization of $33.38B and a trailing P/E ratio of 35.0.

Market Cap
$33.38B
P/E (TTM)
35.0
Forward P/E
34.9
Price/Sales
6.7
Price/Book
12.7
EV/EBITDA
21.2
Beta
1.41
EPS (TTM)
$2.53
Profit Margin
19.3%
ROE
38.5%
Short % of Float
5.0%
Days to Cover
4.4
52W High
$91.48
52W Low
$54.84

5-Year Price History

Latest Annual Financials · FY ending December 31, 2025

Revenue
$4.66B
Gross Profit
$2.80B
Operating Income
$911.80M
Net Income
$836.30M
Free Cash Flow
$1.08B
Total Debt
$1.26B
Cash & Equivalents
$917.70M
Shareholder Equity
$2.75B

Recent Quarterly Earnings (EPS)

QuarterReportedActual EPSEstimateSurprise
Q1 2026April 30, 2026$0.56$0.47+19.1%
Q4 2025February 12, 2026$0.68$0.65+4.6%
Q3 2025October 30, 2025$0.61$0.57+7.0%
Q2 2025July 30, 2025$0.48$0.44+9.1%
Q1 2025May 1, 2025$0.32$0.33-3.0%
Q4 2024February 13, 2025$0.45$0.50-10.0%

Short Interest

FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.

SettlementShares Short% of Shares OutDays to CoverChange
July 15, 202618,654,7244.74%4.4+3.0%
June 30, 202618,109,2684.60%3.6+6.4%
June 15, 202617,017,8204.32%3.2-2.2%
May 29, 202617,394,9294.42%2.1-1.0%
May 15, 202617,564,1394.46%2.8-4.1%
April 30, 202618,320,5774.65%4.0+20.6%
April 15, 202615,190,2683.81%4.1+3.2%
March 31, 202614,716,5093.69%3.5-9.7%

Other Medical Devices Stocks

Frequently Asked Questions

What is DexCom Inc's market cap?

As of August 13, 2026, DexCom Inc (DXCM) has a market capitalization of $33.38B.

What is DexCom Inc's P/E ratio?

DexCom Inc trades at a trailing price-to-earnings (P/E) ratio of 35.0. Its forward P/E is 34.9.

Does DexCom Inc pay a dividend?

DexCom Inc does not currently pay a dividend.

What sector is DXCM in?

DexCom Inc is in the Healthcare sector, specifically the Medical Devices industry.

What is DexCom Inc's short interest?

As of the July 15, 2026 FINRA settlement, 18,654,724 DXCM shares were sold short, or 4.74% of shares outstanding. Days to cover: 4.4. FINRA publishes short interest twice a month, about nine business days after each settlement date.

What was DexCom Inc's revenue?

In its latest reported fiscal year (ending December 31, 2025), DexCom Inc reported revenue of $4.66B and net income of $836.30M.

Ask your own questions about DXCM

Try mrmarket.ai free

Data as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.